Literature DB >> 1672914

Functional myocardial impairment in children treated with anthracyclines for cancer.

S T Yeung1, C Yoong, J Spink, A Galbraith, P J Smith.   

Abstract

A non-invasive exercise method was used to look for myocardial damage in apparently normal children who had received moderate doses of anthracyclines for treatment of cancer. 19 children (mean [SD] age 10.6 [4.3] years) who had received anthracyclines (mean total dose 230 [119] mg/m2) and 10 who had received other cytotoxic drugs (mean age 13.3 [4.9] years) were selected from 263 children attending routine follow-up examinations. They underwent measurement of heart rate, blood pressure, and left ventricular dimensions by echocardiography before and after exercise on a bicycle for a maximum of 10 min. All 29 were in remission. All the subjects showed normal fractional shortening (FS = left ventricular end-diastolic minus end-systolic diameter as a percentage of the end-diastolic diameter) at rest, but the increase in FS on exercise was significantly lower in the children who had received anthracyclines than in those who had not (3 [16]% vs 23 [17]%; p less than 0.05). This difference remained significant after adjustment for age and drug exposure. However, there were no significant differences between the groups in the adjusted mean percentage changes on exercise in heart rate or systolic or diastolic blood pressure. Disease type had no effect on the cardiological indices. Thus, many children who have received anthracyclines may have suffered subclinical myocardial damage. Post-exercise echocardiography seems a useful non-invasive method for detecting such damage. Long-term cardiological follow-up of these patients is needed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1672914     DOI: 10.1016/0140-6736(91)92516-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  18 in total

Review 1.  Avoiding chemotherapy related late effects in children with curable tumours.

Authors:  C R Pinkerton
Journal:  Arch Dis Child       Date:  1992-09       Impact factor: 3.791

2.  Fatal cardiac failure after a single dose of doxorubicin in myeloma-associated cardiac amyloid.

Authors:  M A Devoy; C R Tomson
Journal:  Postgrad Med J       Date:  1992-01       Impact factor: 2.401

3.  Lipid lowering: an important factor in preventing adriamycin-induced heart failure.

Authors:  N Iliskovic; P K Singal
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

4.  Exercise capacity in apparently healthy survivors of cancer.

Authors:  E De Caro; F Fioredda; M G Calevo; A Smeraldi; M Saitta; G Hanau; M Faraci; F Grisolia; G Dini; G Pongiglione; R Haupt
Journal:  Arch Dis Child       Date:  2005-09-27       Impact factor: 3.791

5.  Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.

Authors:  Lubomir Elbl; Hana Hrstkova; Iva Tomaskova; Bohumir Blazek; Jaroslav Michalek
Journal:  Eur J Pediatr       Date:  2005-07-26       Impact factor: 3.183

Review 6.  Anthracyclines and the heart.

Authors:  W Rhoden; P Hasleton; N Brooks
Journal:  Br Heart J       Date:  1993-12

Review 7.  Oncology.

Authors:  J S Malpas
Journal:  Postgrad Med J       Date:  1993-02       Impact factor: 2.401

8.  Doxorubicin-heparin complex: reduction of cardiotoxicity of doxorubicin.

Authors:  Y Mizuno; T Hara; S Tachibana; K Uragoh; K Akazawa; K Ueda
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

9.  Late effects of anthracycline therapy in childhood in relation to the function of the heart at rest and under physical stress.

Authors:  D Lang; F Hilger; J Binswanger; G Andelfinger; W Hartmann
Journal:  Eur J Pediatr       Date:  1995-05       Impact factor: 3.183

10.  Cardiac functional evaluation using vector velocity imaging after chemotherapy including anthracyclines in children with cancer.

Authors:  Jong Hun Park; Yeo Hyang Kim; Myung Chul Hyun; Heung Sik Kim
Journal:  Korean Circ J       Date:  2009-09-30       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.